Expression profiling of suppressive monocytes (CD14+HLA-DRlow/neg) in cancer patients
نویسندگان
چکیده
Background Immune evasion by suppression of host immunity is one of the major mechanisms that tumors use to promote its own survival. We have reported an abundance of immunosuppressive monocytes (CD14+HLA-DRlow/neg) in lymphoma (LYM), multiple myeloma (MM), glioblastoma multiforme (GBM), prostate cancer and renal cell carcinoma (RCC). The number of these cells increases with more aggressive disease and is associated with decreased survival. In this study, we examine the RNA expression profile of monocytes from cancer patients compared to healthy donors (CNTRL) to identify differentially affected functional pathways.
منابع مشابه
Immune independent crosstalk between lymphoma and myeloid suppressor CD14+HLA-DRlow/neg monocytes mediates chemotherapy resistance
We have previously reported a novel phenotype of myeloid suppressors in lymphoma patients characterized by a loss of HLA-DR expression on monocytes, CD14+HLA-DRlow/neg. These cells were directly immunosuppressive and were associated with poor clinical outcome. In this study, we found that lymphoma tumors could have more than 30% of their tumor occupied by CD14+ cells. This intimate spatial conn...
متن کاملCancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DRlo/neg Cells): The Gateway to Improved Responses
Dendritic cells are an important target in cancer immunotherapy based on their critical role in antigen presentation and response to tumor development. The capacity of dendritic cells to stimulate anti-tumor immunity has led investigators to use these cells to mediate anti-tumor responses in a number of clinical trials. However, these trials have had mixed results. The typical method for genera...
متن کاملIntratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma.
PURPOSE Immunotherapeutic strategies to treat patients with renal cell carcinoma (RCC) offer new opportunities for disease management. Further improvements to immunotherapy will require additional understanding of the host response to RCC development. EXPERIMENTAL DESIGN Using a novel approach to understanding the immune status of cancer patients, we previously showed that patients with a cer...
متن کاملCD14+HLA-DRlow/− expression: A novel prognostic factor in chronic lymphocytic leukemia
Currently, no prognostic factors exist for determining the host immune status of chronic lymphocytic leukemia (CLL) patients. Therefore, the present report analyzed cluster of differentiation 14 (CD14)+ human leukocyte antigen (HLA)-DRlow/- myeloid-derived suppressor cells (MDSC) from 49 CLL patients and demonstrated that these cells were significantly expanded in all CLL patients when compared...
متن کاملCetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients
BACKGROUND Myeloid-derived suppressor cells (MDSC) and M2 monocytes/macrophages are two types of suppressive myeloid antigen presenting cells that have been shown to promote tumor progression and correlate with poor prognosis in cancer patients. Tumor antigen specific monoclonal antibodies (mAb) have emerged as important agents for cancer therapy. In addition to the direct inhibition of tumor g...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 1 شماره
صفحات -
تاریخ انتشار 2013